CFTR and stomatitis: In a study comparing FOLFOX+trastuzumab with CF+trastuzumab, grade 3-4 diarrhea was seen in 2.5% of the CF+trastuzumab arm and 9.3% in the FOLFOX+trastuzumab arm; grade 3-4 thrombosis was seen in 8.6% of the CF+trastuzumab arm and 3.5% in the FOLFOX+trastuzumab arm; and grade 3-4 stomatitis was seen in 11% of the CF+trastuzumab arm and 9% in the FOLFOX+trastuzumab arm [22].